CD33 CAR Spacer Design for AML Variant Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute myeloid leukemia (AML) are unsatisfactory, particularly for older patients, with high relapse rates and limited survival rates due to the chemo-refractoriness of leukemic stem cells, and existing CD33 antibodies fail to recognize shorter CD33 variants like CD33ΔE2, limiting therapeutic efficacy.
Innovation Solution
Development of chimeric antigen receptors (CARs) with novel binding domains derived from antibodies that target both CD33FL and CD33ΔE2, combined with optimized spacer regions and activation using cytokines IL-2, IL-7, IL-15, and IL-21, to enhance T cell proliferation and cell lysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy is used to treat AML, then complete remission rates can be achieved in younger patients at 60% to 80%, but treatment outcomes for older patients remain unsatisfactory with 70% dying within a year
Solution Approach 1:
The patent changes the therapeutic approach parameter from conventional chemotherapy to CAR-T cell therapy with optimized spacer regions. This parameter change enables the treatment to be effective across different patient age groups by targeting leukemic stem cells that are resistant to conventional chemotherapy, thereby improving reliability for older patients while maintaining effectiveness for younger patients
Solution Approach 2:
The patent creates a composite CAR structure combining binding domains from antibodies 1H10, 1A9, 1E6, 1D2, or 1B9 with optimized spacer regions (short or intermediate length). This composite structure enables simultaneous recognition of full-length and truncated CD33 variants, providing versatile treatment across different AML presentations and age groups
2Reliability
If CD33 antibody-drug conjugate (gemtuzumab ozogamicin) is added to chemotherapy, then survival improves in defined subsets of patients with newly diagnosed AML, but existing CD33 antibodies fail to recognize shorter CD33 variants like CD33ΔE2, limiting therapeutic efficacy
Solution Approach 1:
The patent develops CARs with binding domains that have universal recognition capability for multiple CD33 variants. The binding domains from antibodies 1H10, 1A9, 1E6, 1D2, or 1B9 can recognize both full-length CD33 and truncated variants (ΔE2, ΔE3, ΔE4), making the CAR-T therapy universally effective across different CD33 expression patterns and patient populations
Solution Approach 2:
The patent optimizes the spacer region parameter (length and composition) to enhance CAR functionality. By adjusting the spacer region between the binding domain and transmembrane domain, the patent improves T cell activation and cytotoxicity while maintaining broad variant recognition, thereby overcoming the limitations of fixed-structure antibodies
3Productivity
If CARs with optimized spacer regions are used, then T cell proliferation and cell lysis are enhanced, but device complexity increases due to multiple antibody domains and spacer optimizations
Solution Approach 1:
The patent segments the CAR structure into distinct functional modules: binding domains from specific antibodies (1H10, 1A9, 1E6, 1D2, or 1B9), optimized spacer regions (short or intermediate), transmembrane domains, and intracellular signaling domains. This segmentation allows for systematic optimization of each module's function while maintaining overall CAR performance and enabling modular design to manage complexity
Data Source
AI summary
Chimeric antigen receptors (CARs) with binding domains derived from a novel suite of human CD33-binding antibodies are described. The CARs include optimized short and intermediate spacer regions. The current disclosure also provides methods of cell expansion/activation processes utilizing IL-2, IL-7, IL-15, and/or IL-21 that improve cellular proliferation and cell lysis of the CARs as described.